# uniQure N.V. (QURE) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/QURE
## Company Profile
- Ticker: QURE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Netherlands
- Tags: Gene Therapy, Rare Disease Gene Therapy, CNS, Rare Disease
## Stock Data
- Close: 45.68 USD
- Market cap: 1687685898.6000001 USD
- Last updated: 2026-09-08
## Business Overview
uniQure is a gene-therapy company focused on rare diseases and neurological disorders. Its platform and clinical programs make it one of the better-known names in viral-vector gene therapy.
## Why The Stock Is Moving

As of Sep 8, 2026, QURE closed up 2.65% at $45.68. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the Netherlands and listed on NASDAQ as an ADR, uniQure has a global gene-therapy footprint.

## Business Model

The business is driven by clinical data, manufacturing capability, and the challenge of turning gene therapy into durable value.

## Landscape Position

uniQure is a classic gene-therapy catalyst name whose valuation is highly sensitive to program and safety outcomes.

## Future Catalysts

- uniQure's catalysts are AMT-130 in Huntington's disease and the rest of its gene-therapy pipeline, where any clean clinical or regulatory step can matter a lot. The company still needs the next update to show the gene-therapy platform can keep building beyond a single program.

## Recent News
- 2017-05-11 11:00 EST — [uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates](https://biopharmsignal.com/news/QURE/uniqure-announces-successful-readministration-of-gene-therapy-in-non-human-prima-e34009a1) — Source: uniQure N.V.
- 2017-05-10 11:00 EST — [uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates](https://biopharmsignal.com/news/QURE/uniqure-presents-new-data-demonstrating-successful-and-effective-transduction-of-2ec51afe) — Source: uniQure N.V.
- 2017-05-09 11:00 EST — [uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress](https://biopharmsignal.com/news/QURE/uniqure-announces-first-quarter-2017-financial-results-and-highlights-recent-com-d0fe2efe) — Source: uniQure N.V.
- 2017-05-01 11:00 EST — [uniQure Announces Company Presentations at Upcoming May Conferences](https://biopharmsignal.com/news/QURE/uniqure-announces-company-presentations-at-upcoming-may-conferences-9c7c20f8) — Source: uniQure N.V.
- 2017-04-26 11:00 EST — [uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference](https://biopharmsignal.com/news/QURE/uniqure-presents-new-preclinical-data-on-amt-130-in-huntington-s-disease-at-chdi-5bfec035) — Source: uniQure N.V.